Copyright
©The Author(s) 2017.
World J Gastroenterol. Aug 28, 2017; 23(32): 5875-5886
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875
Table 2 Principal clinical trials with nab-paclitaxel in metastatic pancreatic cancer
| Study ID | Setting | Study drugs | Phase | Status |
| NCT02993731 | Metastatic | Nab-paclitaxel + Gemcitabine +/-Napabucasin | III | Recruiting |
| NCT02101021 | Metastatic | Nab-paclitaxel + Gemcitabine +/- Momelotinib | III | Active not recruiting |
| NCT02715804 | Metastatic | Nab-paclitaxel + Gemcitabine +/-PEGPH20 | III | Recruiting |
| NCT02436668 | Metastatic | Nab-paclitaxel + Gemcitabine +/- Ibrutinib | II-III | Recruiting |
| NCT02827201 | Metastatic | Sequential Nab-paclitaxel + Gemcitabine /FOLFIRI | II | Active not recruiting |
| NCT02767557 | Metastatic | Nab-paclitaxel + Gemcitabine +/-tocilizumab | II | Recruiting |
| NCT03086369 | Metastatic | Nab-paclitaxel + Gemcitabine +/- Olaratumab | II | Not yet recruiting |
| NCT02879318 | Metastatic | Nab-paclitaxel + Gemcitabine +/- Durvalumab + Tremelimumab | II | Recruiting |
| NCT02399137 | Metastatic | Nab-paclitaxel + Gemcitabine + | II | Recruiting |
| MM-141 | ||||
| NCT02340117 | Metastatic | Nab-paclitaxel + Gemcitabine + | II | Recruiting |
| SGT-53 | ||||
| NCT02124317 | Metastatic | Nab-paclitaxel + S-1 | II | Active not recruiting |
| NCT03076216 | Metastatic | Nab-paclitaxel + Gemcitabine + ONCOsil | II | Not yet recruiting |
| NCT02905578 | Metastatic | Nab-paclitaxel + Gemcitabine + | II | Not yet recruiting |
| High-dose ascorbate | ||||
| NCT02732938 | Metastatic | Nab-paclitaxel + Gemcitabine + PF-04136309 | II | Recruiting |
| NCT02551991 | Metastatic | Nal-Iri or Gemcitabine + | II | Recruiting |
| Nab-paclitaxel | ||||
| NCT03009058 | Metastatic | Nab-paclitaxel + Gemcitabine + | I-II | Not yet recruiting |
| IMM 101 | ||||
| NCT02559674 | Metastatic | Nab-paclitaxel + Gemcitabine + | I-II | Recruiting |
| ALT-803 | ||||
| NCT02705196 | Metastatic | Nab-paclitaxel + Gemcitabine + LOAd703 oncolytic virus | I-II | Recruiting |
| NCT01834235 | Metastatic | Nab-paclitaxel + Gemcitabine + | I-II | Active not recruiting |
| NPC-1C | ||||
| NCT01730222 | Metastatic | Nab-paclitaxel + Gemcitabine + Capecitabine + Cisplatin | I-II | Recruiting |
| NCT02620800 | Metastatic | Nab-paclitaxel + 5-fluorouracil + Leucovorin + Bevacizumab + Oxaliplatin | I-II | Recruiting |
| NCT01506973 | Metastatic | Nab-paclitaxel + Gemcitabine + Hydroxychloroquine | I-II | Recruiting |
| NCT02504333 | Metastatic | Nab-paclitaxel + Gemcitabine followed by FOLFOX | I-II | Recruiting |
| NCT02050178 | Metastatic | Nab-paclitaxel + Gemcitabine + OMP-54F28 | I | Active not recruiting |
| NCT02309177 | Metastatic | Nab-paclitaxel + Nivolumab +/- Gemcitabine | I | Recruiting |
| NCT02514031 | Metastatic | Nab-paclitaxel + Gemcitabine + | I | Recruiting |
| ARQ-761 | ||||
| NCT01934634 | Metastatic | Nab-paclitaxel + Gemcitabine + LCL161 | I | Active not recruiting |
| NCT02101580 | Metastatic | Nab-paclitaxel + Gemcitabine + | I | Active not recruiting |
| ADI-PEG 20 | ||||
| NCT02138383 | Metastatic | Nab-paclitaxel + Gemcitabine + Enzalutamide | I | Active not recruiting |
| NCT02975141 | Metastatic | Nab-paclitaxel + Gemcitabine + Afatinib | I | Recruiting |
| NCT02227940 | Metastatic | Nab-paclitaxel + Gemcitabine + Ceritinib | I | Recruiting |
| NCT02231723 | Metastatic | Nab-paclitaxel + Gemcitabine + | I | Recruiting |
| BBI608 | ||||
| NCT02501902 | Metastatic | Nab-paclitaxel + Palbociclib | I | Recruiting |
- Citation: Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886
- URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5875.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i32.5875